|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing,locally advanced or metastatic gastric or gastroesophageal junction cancer:a single-arm phase II study显示文摘Background:Current treatment options for human epidermal growth factor receptor 2(HER2)-overexpressing gastric cancer at third-line have shown limited clinical benefit.Further,there is no specific treatment for HER2 immunohistochemistry(IHC)2+and fluorescence in-situ hybridization-negative patients.Here,we report the efficacy and safety of a novel anti-HER2 antibody RC48 for patients with HER2-overexpressing,advanced gastric or gastroesophageal junction cancer.Methods:Patients with HER2-overexpressing(IHC 2+or 3+),locally advanced or metastatic gastric or gastroesophageal junction cancer who were under at least second-line therapy were eligible and received RC482.5 mg/kg alone every 2 weeks.The primary endpoint was the objective response rate(ORR)assessed by an independent review committee.Secondary endpoints included progressionfree survival(PFS),overall survival(OS),duration of response,time to progression,disease control rate,and safety.Results:Of 179 patients screened,125 were eligible and received RC48 treatment.The ORR was 24.8%(95%confidence interval[CI]:17.5%-33.3%).The median PFS and OS were 4.1 months(95%CI:3.7-4.9 months)and 7.9 months(95%CI:6.7-9.9 months),respectively.The most frequently reported adverse events were decreased white blood cell count(53.6%),asthenia(53.6%),hair loss(53.6%),decreased neutrophil count(52.0%),anemia(49.6%),and increased aspartate aminotransferase level(43.2%).Serious adverse events(SAEs)occurred in 45(36.0%)patients,and RC48-related SAEs were mainly decreased neutrophil count(3.2%).Seven patients had adverse events that led to death were not RC48-related.Conclusions:RC48 showed promising activity with manageable safety,suggesting potential application in patients with HER2-overexpressing,advanced gastric or gastroesophageal junction cancer who have previously received at least two lines of chemotherapy. | Zhi Peng Tianshu Liu Jia Wei Airong Wang Yifu He Liuzhong Yang Xizhi Zhang Nanfeng Fan Suxia Luo Zhen Li Kangsheng Gu Jianwei Lu Jianming Xu Qingxia Fan Ruihua Xu Liangming Zhang Enxiao Li Yuping Sun Guohua Yu Chunmei Bai Yong Liu Jiangzheng Zeng Jieer Ying Xinjun Liang Nong Xu Chao Gao Yongqian Shu Dong Ma Guanghai Dai Shengmian Li Ting Deng Yuehong Cui Jianmin Fang Yi Ba Lin Shen | 2021 | Cancer Communications2021，41，11： | 29 |
| 2 | Changing Proportions of HIV-1 Subtypes and Transmitted Drug Resistance Among Newly Diagnosed HIV/AIDS Individuals—China,2015 and 2018显示文摘Introduction:With the expansion of human immunodeficiency virus(HIV)antiretroviral therapy(ART),HIV drug resistance is becoming more and more serious.This study describes the changing prevalence of HIV-1 subtypes and transmitted drug resistance(TDR)among newly diagnosed individuals in China,2015 and 2018.Methods:A total of 8,980 individuals in 2015 and 2018 from 31 provincial-level administrative divisions(PLADs)were enrolled in this study.Viral RNAs were amplified and sequenced using an in-house polymerase chain reaction(PCR)protocol.The Stanford HIV Drug Resistance Database(HIVdb)was used to predict susceptibility to 12 antiretroviral drugs.Results:The prevalence of TDR was not significantly increased over time.The prevalence of TDR was 3.8%and 4.4%in 2015 and 2018,respectively(P=0.13).The prevalence of CRF55_01B increased from 2.3%in 2015 to 3.9%in 2018(P<0.001).The drug resistance prevalence of nonnucleoside reverse transcriptase inhibitors(NNRTI)increased from 2.4%in 2015 to 3.3%in 2018(P<0.01).The prevalence of E138(P<0.001),H221(P=0.03),and V179(P<0.001)mutations increased from 0.30%,0.09%,and 0.70%in 2015 to 1.10%,0.30%,and 1.70%in 2018,respectively.Conclusions:HIV drug resistance affects the effect of antiretroviral treatment,so the monitoring of HIV TDR should be strengthened to control the transmission of HIV drug resistance. | Jingjing Hao Shan Zheng Mengze Gan Aobo Dong Ruihua Kang Miaomiao Li Shuai Zhao Jing Hu Chang Song Lingjie Liao Yi Feng Yiming Shao Yuhua Ruan Hui Xing | 2021 | China CDC weekly2021，3，53： | 13 |
| 3 | Comparison of the inhibition potentials of icotinib and erlotinib against human UDP-glucuronosyltransferase 1A1显示文摘UDP-glucuronosyltransferase 1A1(UGT1A1) plays a key role in detoxification of many potentially harmful compounds and drugs. UGT1A1 inhibition may bring risks of drug–drug interactions(DDIs), hyperbilirubinemia and drug-induced liver injury. This study aimed to investigate and compare the inhibitory effects of icotinib and erlotinib against UGT1A1, as well as to evaluate their potential DDI risks via UGT1A1 inhibition. The results demonstrated that both icotinib and erlotinib are UGT1A1 inhibitors, but the inhibitory effect of icotinib on UGT1A1 is weaker than that of erlotinib. The IC_(50) values of icotinib and erlotinib against UGT1A1-mediated NCHN-O-glucuronidation in human liver microsomes(HLMs) were 5.15 and 0.68 μmol/L, respectively. Inhibition kinetic analyses demonstrated that both icotinib and erlotinib were non-competitive inhibitors against UGT1A1-mediated glucuronidation of NCHN in HLMs, with the Kivalues of 8.55 and 1.23 μmol/L, respectively. Furthermore, their potential DDI risks via UGT1A1 inhibition were quantitatively predicted by the ratio of the areas under the concentration–time curve(AUC) of NCHN. These findings are helpful for the medicinal chemists todesign and develop next generation tyrosine kinase inhibitors with improved safety, as well as to guide reasonable applications of icotinib and erlotinib in clinic, especially for avoiding their potential DDI risks via UGT1A1 inhibition. | Xuewei Cheng Xia Lv Hengyan Qu Dandan Li Mengmeng Hu Wenzhi Guo Guangbo Ge Ruihua Dong | 2017 | Acta Pharmaceutica Sinica B2017，7，6： | 7 |
| 4 | Remaining Useful Life Prediction for a Roller in a Hot Strip Mill Based on Deep Recurrent Neural Networks显示文摘Accurate estimation of the remaining useful life(RUL)and health state for rollers is of great significance to hot rolling production.It can provide decision support for roller management so as to improve the productivity of the hot rolling process.In addition,the RUL prediction for rollers is helpful in transitioning from the current regular maintenance strategy to conditional-based maintenance.Therefore,a new method that can extract coarse-grained and fine-grained features from batch data to predict the RUL of the rollers is proposed in this paper.Firstly,a new deep learning network architecture based on recurrent neural networks that can make full use of the extracted coarsegrained fine-grained features to estimate the heath indicator(HI)is developed,where the HI is able to indicate the health state of the roller.Following that,a state-space model is constructed to describe the HI,and the probabilistic distribution of RUL can be estimated by extrapolating the HI degradation model to a predefined failure threshold.Finally,application to a hot strip mill is given to verify the effectiveness of the proposed methods using data collected from an industrial site,and the relatively low RMSE and MAE values demonstrate its advantages compared with some other popular deep learning methods. | Ruihua Jiao Kaixiang Peng Jie Dong | 2021 | IEEE/CAA Journal of Automatica Sinica2021，8，7： | 5 |
| 5 | Post-marketing safety surveillance and reevaluation of Motherwort injection:A clinical study of 10094 cases显示文摘OBJECTIVE:To investigate the safety profiles of Motherwort injection(MI).METHODS:A multi-center,prospective and drugderived hospital intensive monitoring method was conducted to assess the safety of MI in real world applications.This study was based on a very large population after the injection was approved and marketed in China.All patients using the injection in participating hospitals were monitored to determine the incidence,pattern,severity and outcome of associated adverse events.RESULTS:The post-marketing surveillance was performed in 10 094 female patients from April to December,2015.The incidence of adverse drug reactions(ADRs) was 0.79‰(8/10 094).Among the 8 patients,the reported adverse events mainly included systemic abnormalities,such as fever,chills and eyelid edema;skin and appendages disorders,such as pruritus and rash;gastrointestinal disorders,such as nausea,abdominal distension and pain;heart rate and rhythm disorders,such as palpitation and increased heart rate.All of these ADRs were mild in severity.CONCLUSION:In this study the ADRs incidence rate of MI is very low,which supports that it is generally safe for use in obstetric and gynecological diseases.However,the total number of 8 ADRs recorded over a relatively short time span seems limited,and the low number of reports could not represent an absolute guarantee of safety. | Cao Shan Zhang Wenhao Zhao Ziwei Heng Mingli Bu Huaien Wang Hongwu Liu Xinghui Wang Zhong Cai Yan Ma Yuyan Cui Shihong Deng Jihong Ding Guifeng Ding Yajuan Dong Linhong Duan Zhentao Fan Ling Fan Yang Fu Fen He Jing Ji Shuying Jin Lin Li Hong Li Hongying Liao Tao Lu Wei Luo Xiucui Lü Zhihui Ma Fengchun Ma Dafeng Shi Tianyun Sun Juying Sun Xiaotong Teng Hong Wang Jinhua Wang Ruihua Wang Ying Wang Zhengling Xi Jie Xu Minjuan Xu Zhihong Yan Qian Yang Cuirong Yang Yimei Yin Jie Yu Jinhua Yuan Wenjun Zhang Guanli Zhang Meihua Zhao Renfeng Zhong Yonghong Zhou Jian | 2018 | Journal of Traditional Chinese Medicine2018，38，4： | 4 |
| 6 | Fibrinolytic Evaluation of Compounds Isolated from a Marine Fungus Stachybotrys Iongispora FG216显示文摘 | Ruihua Guo Yiting Zhang Dong Duan Qiang Fu Xiangyu Zhang Xiaowei Yu Shujun Wang Bin Bao Wenhui Wu | 2016 | Chinese Journal of Chemistry2016，34，11： | 4 |
| 7 | Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of CRAF and MEK1/2显示文摘Constitutive activation of RAS-RAF-MEK-ERK signaling pathway(MAPK pathway)frequently occurs in many cancers harboring RAS or RAF oncogenic mutations.Because of the paradoxical activation induced by a single use of BRAF or MEK inhibitors,dual-target RAF and MEK treatment is thought to be a promising strategy.In this work,we evaluated erianin is a novel inhibitor of CRAF and MEK1/2 kinases,thus suppressing constitutive activation of the MAPK signaling pathway induced by BRAF V600E or RAS mutations.KinaseProfiler enzyme profiling,surface plasmon resonance(SPR),isothermal titration calorimetry(ITC),cellular thermal shift assay,computational docking,and molecular dynamics simulations were utilized to screen and identify erianin binding to CRAF and MEK1/2.Kinase assay,luminescent ADP detection assay,and enzyme kinetics assay were investigated to identify the efficiency of erianin in CRAF and MEK1/2 kinase activity.Notably,erianin suppressed BRAF V600E or RAS mutant melanoma and colorectal cancer cell by inhibiting MEK1/2 and CRAF but not BRAF kinase activity.Moreover,erianin attenuated melanoma and colorectal cancer in vivo.Overall,we provide a promising leading compound for BRAF V600E or RAS mutant melanoma and colorectal cancer through dual targeting of CRAF and MEK1/2. | Penglei Wang Xuechao Jia Bingbing Lu Han Huang Jialin Liu Xuejiao Liu Qiong Wu Yamei Hu Pan Li Huifang Wei Tingting Liu Dengyun Zhao Lingwei Zhang Xueli Tian Yanan Jiang Yan Qiao Wenna Nie Xinli Ma Ruihua Bai Cong Peng Zigang Dong Kangdong Liu | 2023 | Signal Transduction and Targeted Therapy2023，8，4： | 1 |
| 8 | VEGF-A not Ang2 mediates endothelial-like differentiation of immatureDCs by ERK1/2 signaling in the microenvironment of human colon adenocarcinoma显示文摘 | Jing Lu Kangdong Liu Jimin Zhao Jun Zhao Junfen Ma Hongyan Yang Youtian Huang Zhenzhu Qin Ruihua Bai Lili Jiang Fengshou Lv Pei Li Wenhai Yan Mingyao Zhao Ziming Dong | 2011 | International Journal of Oncology2011，，6： | 1 |
| 9 | Impact of HIV Pretreatment Drug Resistance on Virological Failure After One-Year Antiretroviral Therapy--China,2018-2019显示文摘Summary What is already known about this topic?While antiretroviral therapy(ART)has been rapidly scaled-up among the population living with human immunodeficiency virus or acquired immune deficiency syndrome(HIV/AIDS)patients since 2016,pretreatment drug resistance(PDR)has also increased. | Miaomiao Li Chang Song Aobo Dong Jing Hu Ruihua Kang Hui Xing Yuhua Ruan Yiming Shao Kunxue Hong Lingjie Liao | 2022 | China CDC weekly2022，4，25： | 0 |
| 10 | CLEAR:a full-stack chip-in-loop emulator for analog RRAM based computing-in-memory system显示文摘Deep neural networks(DNNs)have undergone tremendous advancement in several practical applications,such as object detection and text generation,over the last few years,leading to a huge demand for increased computing efficiency of hardware.Resistive random-access memory(RRAM)-based computing-in-memory(CIM)chip has been investigated as a promising candidate to reduce the requirement for memory bandwidth[1]. | Ruihua YU Wenqiang ZHANG Bin GAO Yiwen GENG Peng YAO Yuyi LIU Qingtian ZHANG Jianshi TANG Dong WU Hu HE Ning DENG He QIAN Huaqiang WU | 2023 | Science China(Information Sciences)2023，66，12： | 0 |
| 11 | Analysis of γ-Hydroxybutyrate in Human Urine by LC-MSIMS Method and Its Forensic Application显示文摘 | Luan Yujing Wang Ruihua Dong Ying | 2017 | Journal of Chemistry and Chemical Engineering2017，11，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员